MedPath

DRI Healthcare Trust Acquires Royalty Interest in KalVista's Seb способов лечения Hereditary Angioedema Drug

• DRI Healthcare Trust has acquired a royalty interest in sebetralstat, an oral on-demand therapy for hereditary angioedema (HAE), from KalVista Pharmaceuticals. • The agreement includes an upfront payment of US$100 million, potential milestone payments up to US$57 million, and a US$5 million equity investment in KalVista. • Seb способов лечения Hereditary Angioedema is under regulatory review by the FDA and EMA, with a PDUFA date set for June 17, 2025. • The investment aligns with DRI Healthcare Trust's strategy to finance innovation in the life sciences and diversify its portfolio with long-term assets.

DRI Healthcare Trust has announced the acquisition of a royalty interest in sebetralstat, an investigational oral therapy developed by KalVista Pharmaceuticals for the on-demand treatment of hereditary angioedema (HAE). The deal, valued at up to US$184 million, includes a US$100 million upfront payment, up to US$57 million in sales-based milestone payments, and a US$5 million investment in KalVista's common stock.

Seb способов лечения Hereditary Angioedema: A Promising Oral Treatment for HAE

HAE is a rare genetic disorder characterized by recurrent episodes of severe swelling in various body parts. Seb способов лечения Hereditary Angioedema, a novel oral plasma kallikrein inhibitor, has demonstrated significant efficacy and a favorable safety profile in clinical trials, offering a potential alternative to existing injectable treatments. The FDA has accepted KalVista's New Drug Application (NDA) for sebetralstat, with a Prescription Drug User Fee Act (PDUFA) date of June 17, 2025. The European Medicines Agency (EMA) has also validated the Marketing Authorization Application (MAA) for sebetralstat.
The Phase III KONFIDENT trial, a randomized, double-blind, placebo-controlled study, enrolled 136 adult and adolescent HAE patients. Results showed sebetralstat significantly reduced the time to symptom relief, attack severity, and complete attack resolution compared to placebo. The safety profile was similar to that of placebo.

Financial Terms and Royalty Structure

Under the agreement, DRI Healthcare Trust will receive a tiered royalty on net sales of sebetralstat: 5.00% on sales up to US$500 million, 1.10% on sales between US$500 million and US$750 million, and 0.25% on sales above US$750 million. KalVista is also eligible for a one-time sales-based milestone payment of US$50 million if annual worldwide net sales exceed US$550 million before January 1, 2031. An optional US$22 million payment to KalVista, if exercised, would increase the royalty rate on sales up to US$500 million to 6.00% and the milestone payment to US$57 million.

Strategic Implications for DRI Healthcare Trust

This acquisition marks DRI Healthcare Trust's first pre-approval royalty acquisition and equity investment, highlighting its evolving investment strategy. Ali Hedayat, Acting CEO of the Trust's investment manager, noted that sebetralstat's robust clinical data and potential long duration of cash flows make it an attractive asset. Navin Jacob, Chief Investment Officer, expressed confidence in sebetralstat's potential to become a foundational treatment for HAE.
KalVista intends to use the proceeds from the transaction to fund the continued clinical development and commercialization of sebetralstat. The royalty receipts for DRI Healthcare Trust are anticipated to continue through at least 2041.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

IDEAYA Biosciences Licenses DLL3-Targeting ADC from Hengrui Pharma in $1B Deal

IDEAYA Biosciences has secured an exclusive license from Hengrui Pharma for SHR-4849, a DLL3-targeting antibody-drug conjugate (ADC), outside of Greater China.
SHR-4849 is currently in Phase 1 trials and has demonstrated promising antitumor activity in preclinical studies, particularly in small cell lung cancer (SCLC).

Supriya Lifescience Receives Brazil Approval for Esketamine Hydrochloride and Files Patent for Atorvastatin Synthesis

Supriya Lifescience has secured approval from Brazil's ANVISA for Esketamine Hydrochloride, marking the first Indian company to achieve this milestone.
The approval allows Supriya Lifescience to expand its portfolio in Brazil and the broader LATAM region, addressing the growing demand for affordable mental health treatments.

Sebetralstat Shows Promise for Early Treatment of Hereditary Angioedema in Phase 3 Trial

Phase 3 KONFIDENT trial data suggests earlier treatment with sebetralstat leads to faster resolution of hereditary angioedema (HAE) attacks.
Sebetralstat significantly reduced symptom burden compared to placebo, with symptom relief achieved in approximately 5 hours for moderate to severe attacks.

Relief Therapeutics Receives $2 Million Milestone Payment After FDA Approval of Arimoclomol

Relief Therapeutics will receive a $2 million milestone payment from SWK Funding LLC following the FDA approval of Zevra Therapeutics' arimoclomol.
The FDA approved arimoclomol (MIPLYFFA) for treating neurological manifestations of Niemann-Pick Disease Type C in patients aged 2 years and older.

KalVista's Sebetralstat Advances Toward Potential Approval for Hereditary Angioedema

KalVista Pharmaceuticals' NDA for sebetralstat, an oral plasma kallikrein inhibitor, has been accepted by the FDA for on-demand treatment of hereditary angioedema (HAE) attacks.
The FDA has set a PDUFA goal date of June 17, 2025, for sebetralstat, marking a significant step toward potential market availability.

KalVista Seeks Global Approval for Oral HAE Treatment Sebetralstat

KalVista Pharmaceuticals has submitted Marketing Authorization Applications (MAAs) for sebetralstat in the UK, Switzerland, Australia, and Singapore.
Sebetralstat, an oral treatment for hereditary angioedema (HAE), could be the first on-demand oral medication for HAE attacks in patients 12 and older.

Sarepta's Elevidys Receives Expanded FDA Approval for Duchenne Muscular Dystrophy

The FDA has granted expanded approval to Sarepta Therapeutics' Elevidys for treating Duchenne muscular dystrophy (DMD) patients, broadening the eligible patient population.
Elevidys, a gene therapy, now includes ambulatory and non-ambulatory DMD patients, marking a significant advancement in treatment options.

Sarepta's Elevidys Receives Full FDA Approval for Expanded Use in Duchenne Muscular Dystrophy

The FDA granted full approval for Sarepta's Elevidys gene therapy for Duchenne muscular dystrophy (DMD) patients aged 4 and older with confirmed DMD gene mutations.
Accelerated approval was also granted for non-ambulatory patients, contingent on Phase III study results, marking a significant label expansion for Elevidys.

KalVista Submits NDA to FDA for Oral Sebetralstat in Hereditary Angioedema

KalVista Pharmaceuticals has submitted a New Drug Application (NDA) to the FDA for sebetralstat, an oral plasma kallikrein inhibitor, for on-demand treatment of hereditary angioedema (HAE).
The NDA is supported by Phase 3 KONFIDENT trial data, which demonstrated sebetralstat's ability to achieve significantly faster symptom relief compared to placebo in HAE patients.

Denali's Hunter Syndrome Candidate Receives FDA Orphan Drug and Rare Pediatric Disease Designations

Denali Therapeutics Inc. announced that its pipeline candidate, DNL310, has been granted orphan drug status and a rare pediatric disease designation by the FDA for the treatment of Hunter Syndrome, a rare lysosomal storage disease. The company plans to initiate a phase I/II study in 2020, following promising pre-clinical results.

Reference News

[1]
DRI Healthcare Trust Announces Acquisition of a Synthetic Royalty Interest in the ... - Markets data
markets.ft.com · Nov 4, 2024

DRI Healthcare Trust acquires royalty interest in sebetralstat from KalVista for up to $179M, including $100M upfront, $...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy